Reactivation of fetal haemoglobin (HbF) expression in adult life could provide an effective therapeutic approach for patients with haemoglobinopathies and thalassaemias. Among HbF induction agents, hydroxycarbamide (HC) has been successfully used to treat sickle cell disease (SCD) and selected thalassaemia syndromes ([@b16]; [@b24]; [@b5]). Hydroxycarbamide is believed to exert its beneficial effects in SCD via a variety of mechanisms, including augmented HbF synthesis by erythroid regeneration or NO-related increases in soluble guanylate cyclase activity and cyclic guanidine monophosphate (cGMP) that stimulate *HBG* expression ([@b3]). Additional mechanisms may also include myelosuppression with a reduction in circulating neutrophils, increased erythrocyte water content, modified erythrocyte endothelial cell interactions and altered vascular tone by increasing NO bioavailability ([@b13]). Many patients treated with HC increase HbF levels from baseline, with wide variability in the magnitude of this response. The underlying reasons for this spectrum of HC responsiveness are poorly understood ([@b19]; [@b1]).

Presently, a major research priority is the identification of genetic variants underlying both human diseases and differences in pharmacological responsiveness to drugs ([@b4]). In SCD, this paradigm is being applied to elucidate the pathogenesis of vaso-occlusive and vascular complications and to develop individualized SCD therapies ([@b18]). Genetic variants in drug-metabolizing enzymes, transporters or targets could potentially influence the efficacy or toxicity of drugs used in SCD. The HC-induced small guanosine triphosphate (GTP)-binding protein, secretion-associated and RAS-related (SAR) protein has recently been shown to play a pivotal role in *HBG* induction by causing cell apoptosis and G1/S-phase arrest by reduction of phosphatidylinositol 3 (PI3) kinase and extracellular protein-related kinase (ERK) phosphorylation with increased p21 and GATA-2 expression ([@b21]).

*SAR1A* belongs to the small GTPase superfamily and encodes a GTP-binding protein SAR1a. This protein plays a key role in initializing transport from the endoplasmic reticulum (ER) to the Golgi apparatus. The localization of *SAR1A* in the endoplasmic reticulum and its association with *HBG* expression demonstrated in our recent study suggest that *SAR1A* also plays a special role in haemoglobin regulation ([@b21]). However, the precise pathway(s) through which *SAR1A* regulates *HBG* remain unknown. *SAR1A* may increase the transport of membrane-bound transcription factor precursors from the ER to the Golgi. The proteolytic cleavage of the precursor proteins in the Golgi activate cytosolic fragments that enter the nucleus and regulate erythroid-specific transcription factors, such as GATA, eventually modulating *HBG* expression. Moreover, previous studies have illuminated a pivotal role of the p38 mitogen-activated protein kinase (MAPK) pathway during GTP-mediated erythroid differentiation of K562 cells with the accumulation of *HBG* mRNA ([@b14]; [@b11]). Activators of the soluble guanylate cyclase (sGC) and protein kinase G (PKG) pathways have been implicated in the regulation of *HBG* expression in both erythroleukemic cells and in primary erythroblasts ([@b8]). Expression of *HBG* and the sGC alpha subunit are correlated, indicating that GTP-binding proteins may participate in *HBG* induction.

Preliminary data from our study indicated that HC inducibility is transcriptionally regulated and localized to elements in the *SAR1A* promoter. Accordingly, we hypothesized that DNA sequence variation within the *SAR1A* promoter might explain differences in individual responses to HC therapy. To test this hypothesis, we identified the single nucleotide polymorphism (SNPs) in the *SAR1A* promoter by DNA sequencing and examined these variants in an association study of sickle cell anaemia patients treated with HC.

Materials and methods
=====================

Subjects
--------

DNA samples and laboratory data were from unrelated individuals with SCD who enrolled in a Sickle Cell Pulmonary Hypertension Screening Study at the National Institutes of Health (NIH) and Howard University (ClinicalTrials.gov Identifier: NCT00011648). The study had enrolled 282 subjects as of December, 2005, of which 269 had sufficient clinical data for inclusion in the present study ([@b22]). All subjects were at least 18 years of age and provided written informed consent for participation in this Institutional Review Board (IRB) approved protocol. Cases and controls were defined as adults with SCD who were treated with or without HC respectively. Additionally, 32 of these 269 subjects had quantitative high performance liquid chromatography (HPLC) HbF measurements and other laboratory values determined prior to and during HC therapy. The mean length of follow-up evaluation for patients with HbF measured at the end of the study was 21 months (maximum, 33 months; minimum, 8 months). DNA was also available from 117 newborns identified with SCD by a state newborn screening program during a single calendar year, where DNA was collected anonymously with prospective exemption from IRB review.

Polymerase chain reaction (PCR) and DNA sequencing
--------------------------------------------------

A 2265 base pair fragment which included the *SAR1A* upstream promoter region, exon 1, and a portion of intron 1 was amplified using gene-specific primers: forward primer, 5′ ATGTGCACAACAATGCCTGT 3′; reverse primer, 5′ GAAACTGTTATCCGGCCCAG 3′. The PCR conditions were an initial denaturation at 95°C for 3 min, followed by 35 cycles at 95°C for 45 s, 56°C for 1 min and 2 min at 72°C. Finally an additional elongation step was carried out at 72°C for 7 min. The PCR products were purified using QIAquick PCR purification kit (Qiagen, Valencia, CA, USA). Purified PCR products were directly sequenced in both directions by using Big Dye chemistry (Applied Biosystems, Foster City, CA, USA). The BioEdit and Clustal W programs were used to multiple align individual sequences with the reference sequence (GenBank accession number: NT008583 or March, 2006 assembly hg18: chr10:71599909-71602173).

Statistical analysis
--------------------

Comparisons of genotype and allele frequencies between cases and controls were carried out using chi-squared tests of association. Three genetic models (dominant, codominant and recessive) for modulation of response to HC treatment were tested. Genotype specific risks were estimated as odds ratio (OR) with 95% confidence intervals (95% CI). Multiple logistic regression (JMP 6.0.3) was used to investigate the association between individual SNPs and the change in HbF level after HC treatment. Haplotypes were determined using Phase 2.1 ([@b20]). Probability differences of *P* \< 0·05 were considered as statistically significant without additional correction for multiple comparisons.

Results
=======

Of 282 enrolled adults at NIH, 13 patients were excluded because of incomplete data. The majority was Hb SS (202 cases, 71·6%), 44 haemoglobin SC (15·6%), 16 sickle β^+^-thalassaemia (5·7%), 4 sickle β^0^-thalassaemia (1·4%), two haemoglobin SD (0·7%), one haemoglobin SOArab (0·4%) and two with incompletely characterized sickle β-thalassaemia (0·7%). The presence of coincident α-thalassaemia (α^3·7^ deletion) was also determined for 260 SCD subjects (92·2%, *n* = 282): 179 (68·8%) with αα/αα, 73 (28·1%) with −α/αα, seven (2·7%) with −α/−α and one (0·4%) with ααα/αα. No α^4·2^ deletions were detected (89·4%, *n* = 252 out of total 282) ([@b22]).

In order to determine the pattern of mutation and polymorphism across putative HC responsive regulatory elements in SCD patients, we designed sequence-specific primers corresponding to a 2·3 kb fragment of *SAR1A* on chromosome 10 which was completely sequenced in all subjects. Twenty DNA sequence variants, including two insertion/deletion polymorphisms and nine that have been previously reported in dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/index.html>), were identified among a total of 386 patients, consisting of 269 adults at NIH and 117 newborns with SCD. Fourteen variants were within the upstream promoter region, four SNPs were in the 5′UTR encoded within exon 1 (+14 T\>A, rs3812693, +31 T\>C and rs3812692), and 2 SNPs were within the first intron (rs4282891 and intron 1 + 140 C\>G). Using Phastcons genomic sequence alignments from 17 vertebrate species including Homo sapiens (<http://www.genome.ucsc.edu>; May, 2004 hg17 assembly), we identified phylogenetically conserved blocks of sequence across this 2·3 kb region of *SAR1A*. Four SNPs (−30 C\>G, +14 T\>A, rs4282891 and intron 1 + 140 C\>G) corresponded to highly conserved non-coding nucleotide sites (Phastcons scores \>0·4), which is strongly suggestive of an increased likelihood that these SNPs represent functional variants.

When *SAR1A* sequence data were compared between NIH subjects and the newborn SCD cohort, differences in genotype frequency were observed for rs2310991 in the upstream promoter region \[Odds ration (OR) = 1·9, 95% CI = 1·1−3·2, *P* = 0·009\] and +31 T\>C in the 5′UTR \[OR 9·8 (1·3-73·9); 95% CI; *P* \< 0·001\] (data not shown).

Individual *SAR1A* variants were then analysed for association with HbF levels, expressed as percentage of total haemoglobin (%) or as absolute HbF (g/l), among 176 adults with homozygous SCD (SS) treated with or without HC (69 cases vs. 107 cases). Three SNPs in the upstream promoter region (−809 C\>T, −502 G\>T and −385 C\>A) were significantly associated with higher percentage HbF under a co-dominant genetic model even after statistical correction ([Table I](#tbl1){ref-type="table"}). The major allele frequency of −809 C\>T, −502 G\>T and −385 C\>A were 0·93, 0·98 and 0·96 respectively. When the analysis was repeated using absolute HbF concentration as a clinical endpoint between HC cases and SS controls, only one of these three markers showed evidence for an association (SNP −502 G\>T; data not shown). None of the 20 variants were associated with total haemoglobin levels as the outcome measure between cases and controls (data not shown).

###### 

SNPs associated with a higher percent HbF (%HbF) with hydroxycarbamide treatment.

  SNP                                                                           rs Number    Ch 10 map position   Dominant                                     Codominant                                       Recessive                                    Major allele frequency
  ----------------------------------------------------------------------------- ------------ -------------------- -------------------------------------------- ------------------------------------------------ -------------------------------------------- ------------------------
  −1377 (G\>T)[\*](#tf1-1){ref-type="table-fn"}                                 rs2310991    71601652             **0·0027**[‡](#tf1-3){ref-type="table-fn"}   **0·0218**                                       0·1369                                       0·45
  −809 (C\>T)                                                                   rs76901216   71601084             **0·0413**                                   **0·0008**[‡](#tf1-3){ref-type="table-fn"}       ND                                           0·93
  −743 (G\>A)[\*](#tf1-1){ref-type="table-fn"}                                  rs10999169   71601018             **0·0418**                                   **0·0108**                                       **0·0079**                                   0·77
  −605/−606 (--\>T)[\*](#tf1-1){ref-type="table-fn"}                            rs11438971   71600880/71600879    ND                                           ND                                               **0·0231**                                   0·01
  −502 (G\>T)                                                                   rs76901217   71600777             **0·0300**                                   **2·1266E-07**[‡](#tf1-3){ref-type="table-fn"}   ND                                           0·98
  −460 (C\>G)                                                                   rs76901218   71600735             **0·0084**                                   **0·0129**                                       ND                                           0·98
  −432 (T\>--)[\*](#tf1-1){ref-type="table-fn"}                                 rs11284333   71600707             **0·0199**                                   ND                                               **0·0319**                                   0·61
  −420 (TTTT\>--)[\*](#tf1-1){ref-type="table-fn"}                              rs10577419   71600699             **0·0310**                                   ND                                               **0·0117**                                   0·60
  −417 (T\>--)[\*](#tf1-1){ref-type="table-fn"}                                 rs5785963    71600692             **0·0258**                                   ND                                               **0·0140**                                   0·61
  −396 (T\>C)                                                                   rs76901219   71600671             **0·0264**                                   ND                                               ND                                           0·98
  −385 (C\>A)                                                                   rs76901220   71600660             **0·0344**                                   **1·0610E-07**[‡](#tf1-3){ref-type="table-fn"}   ND                                           0·96
  −372 (G\>A)                                                                   rs76901221   71600647             **0·0161**                                   0·0833                                           **0·0027**[‡](#tf1-3){ref-type="table-fn"}   0·89
  −45 (G\>A)                                                                    rs76901222   71600320             **0·0348**                                   0·5382                                           ND                                           0·98
  −30 (C\>G)                                                                    rs76901223   71600305             **0·0264**                                   ND                                               ND                                           1·00
  +14 (T\>A)[†](#tf1-2){ref-type="table-fn"}                                    rs76901224   71600262             **0·0288**                                   ND                                               ND                                           1·00
  +27 (C\>A)[\*](#tf1-1){ref-type="table-fn"}[†](#tf1-2){ref-type="table-fn"}   rs3812693    71600249             **0·0146**                                   **0·0284**                                       ND                                           0·98
  +31 (T\>C)[†](#tf1-2){ref-type="table-fn"}                                    rs76901225   71600245             **0·0159**                                   0·6734                                           ND                                           ·95
  +68 (C\>T)[\*](#tf1-1){ref-type="table-fn"}[†](#tf1-2){ref-type="table-fn"}   rs3812692    71600208             **0·0228**                                   ND                                               ND                                           0·99
  Intron 1 + 100 (G\>A)[\*](#tf1-1){ref-type="table-fn"}                        rs4282891    71600075             **0·0193**                                   0·8913                                           ND                                           0·98
  Intron 1 + 140 (C\>G)                                                         rs76901226   71600035             **0·0267**                                   ND                                               ND                                           0·99

Previously reported in dbSNP.

Present within the 5′ UTR.

Significant *P*-value after Bonforoni correction.

Bold: SNP with *P*-value ≤ 0·05.

ND, not determined.

Major allele frequency was calculated from genotype frequency of Hb SS patients.

In addition, 32 of the Hb SS subjects had prospective, regular clinical evaluations including quantitative HbF measurements before and during 2 years of HC therapy. When this patient subset was analysed, only rs2310991 was significantly associated with the change in the percentage of HbF. However, four markers (rs2310991, −809 C\>T, −385 C\>A and rs4282891) were significantly associated with the change of absolute HbF concentration. The most statistically significant *P*-value for an association was at rs4282891 (*P* = 0·0012), which is phylogenetically conserved in vertebrates (Phastcons score = 0·5984) and present intron 1 of *SAR1A* ([Table II](#tbl2){ref-type="table"}).

###### 

SNPs associated with a significant change in HbF levels after 2 years of hydroxycarbamide treatment in 32 adults with sickle cell anaemia.

  SNP                                                                           rs Number    Ch10 map position   \% HbF       Absolute HbF
  ----------------------------------------------------------------------------- ------------ ------------------- ------------ --------------
  −1377 (G\>T)[\*](#tf2-1){ref-type="table-fn"}                                 rs2310991    71601652            **0·0229**   **0·0338**
  −809 (C\>T)                                                                   rs76901216   71601084            0·0584       **0·0270**
  −743 (G\>A)[\*](#tf2-1){ref-type="table-fn"}                                  rs10999169   71601018            0·0806       0·2591
  −605/−606 (--\>T)[\*](#tf2-1){ref-type="table-fn"}                            rs11438971   71600880/71600879   0·0720       0·1514
  −502 (G\>T)                                                                   rs76901217   71600777            0·3569       0·9125
  −460 (C\>G)                                                                   rs76901218   71600735            0·8546       0·8040
  −432 (T\>--)[\*](#tf2-1){ref-type="table-fn"}                                 rs11284333   71600707            0·8719       0·4418
  −420 (TTTT\>--)[\*](#tf2-1){ref-type="table-fn"}                              rs10577419   71600699            0·5861       0·7434
  −417 (T\>--)[\*](#tf2-1){ref-type="table-fn"}                                 rs5785963    71600692            0·6116       0·4440
  −396 (T\>C)                                                                   rs76901219   71600671            0·5035       0·4804
  −385 (C\>A)                                                                   rs76901220   71600660            0·0584       **0·0270**
  −372 (G\>A)                                                                   rs76901221   71600647            0·6441       0·3167
  −45 (G\>A)                                                                    rs76901222   71600320            0·1490       0·1560
  −30 (C\>G)                                                                    rs76901223   71600305            ND           ND
  +14 (T\>A)[†](#tf2-2){ref-type="table-fn"}                                    rs76901224   71600262            0·3151       0·9402
  +27 (C\>A)[\*](#tf2-1){ref-type="table-fn"}[†](#tf2-2){ref-type="table-fn"}   rs3812693    71600249            ND           ND
  +31 (T\>C)[†](#tf2-2){ref-type="table-fn"}                                    rs76901225   71600245            0·3483       0·9676
  +68 (C\>T)[\*](#tf2-1){ref-type="table-fn"}[†](#tf2-2){ref-type="table-fn"}   rs3812692    71600208            ND           ND
  Intron 1 + 100 (G\>A)[\*](#tf2-1){ref-type="table-fn"}                        rs4282891    71600075            0·2078       **0·0012**
  Intron 1 + 140 (C\>G)                                                         rs76901226   71600035            0·4313       0·8147

Previously reported in dbSNP.

Present within the 5′ UTR.

Bold: SNP with *P*-value ≤ 0·05.

ND, not determined.

Considering all 20 markers, there were 64 total haplotypes including seven common haplotypes (\>5% frequency) spanning 1617 nucleotides. Significant individual associations observed for markers −809 C\>T, −502 G\>T, and −385 C\>A in the overall population and the 32 prospective follow-up subjects reflected a co-dominant haplotypic effect for the TGA variant (*n* = 23, 4·6%) and CGC wild type (*n* = 447, 89·8%) *SAR1A* promoter haplotypes.

Discussion
==========

HC therapy in sickle cell anaemia increases the circulating HbF concentration in most individuals, although a large proportion of compliant patients experience either a complete failure to respond or have a small, clinically insignificant increase in HbF ([@b10]). Even among patients who are identified as HC responders, the magnitude of HbF increase is variable ([@b2]; ; [@b19]; [@b25]; [@b1]; [@b10]). Presently, the underlying reason for this variability is not known ([@b19]; [@b1]).

Our previous work identified a novel role of *SAR1A* in *HBG* induction that is distinct from its previously established protein-trafficking function. *SAR1A* participates in *HBG* expression and erythroid cell maturation after HC treatment by regulating PI3 kinase/ERK and GATA-2/p21-dependent signal transduction pathways ([@b21]). These results led us to hypothesize that functional polymorphisms in regulatory elements of HC inducible genes, like *SAR1A*, modulate HbF levels or HC therapeutic responses. The present study identified all of the common nucleotide variants across a 2·3 kb region, which includes the promoter and first exon of *SAR1A*, including a subset of markers that are associated with either differences in HbF levels or change in HbF levels in sickle cell anaemia patients treated with HC. Individual associations with higher HbF concentration in HC-treated patients were detectable under three different genetic models ([Table I](#tbl1){ref-type="table"}), in addition to a more rigorous logistic regression association analysis of a subset of prospectively treated patients ([Table II](#tbl2){ref-type="table"}). Similar to our present findings in *SAR1A*, all of the presently known SNP markers in HC inducible genes associated with higher HbF are located within either promoter regions or the first intron 1 of candidate genes ([@b10]). In the slightly larger population studied by [@b10], variants in genes like *FLT1*, *ARG2*, *HAO2* and *NOS1* influenced HbF treatment response. Collectively, these association studies suggest that a specific transcriptionally regulated gene expression profile may be initiated by HC therapy and that genetic variants within regulatory elements of these genes could modulate this response.

Comparative sequence analysis and cross-species conservation have previously been used to identify putative genes and regulatory elements in small genomic regions, suggesting that this is a viable approach for hypothesis generation and fine mapping functional variants underlying genetic association studies ([@b15]; [@b23]). Conserved sites within a 2·3 kb region of *SAR1A* were identified using the University of California Santa Cruz phastCons algorithm, which is based on a two state phylogenetic hidden Markov model that determines a likelihood ratio for conservation at a single nucleotide site across vertebrates ([@b17]). We identified four variants, including three previously unknown markers (−30 C\>G, +14 T\>A, rs4282891 and intron 1 + 140 C\>G), occurring at highly conserved *SAR1A* nucleotides. Thus, these variants are priority candidates for additional study to evaluate their role in regulating *SAR1A* transcription, potentially such using novel methods as high throughput transcriptional profiling for cloned promoter haplotypes in response to therapeutic agents like HC ([@b7]).

*SAR1A* joins an expanding list of candidate loci including the genes listed above and regions of chromosomes 6q, 8q and Xp that might modulate HbF expression or HC responses. In humans, there are two SAR genes; *SAR1A* on chromosome 10 and *SAR1B* on chromosome 5. Although, these paralogs share high degree of amino acid sequence homology (89·4%), their expression patterns are distinct. *SAR1A* is expressed ubiquitously, most abundantly in prostate, thyroid and adrenal gland while *SAR1B* has a tissue-specific pattern with moderate expression in heart, liver, skeletal muscle and testis ([@b6]; [@b21]). These differences in expression patterns suggest different biological roles in various tissues and involvement in different human disease processes. Indeed, *SAR1B* mutations cause lipid absorption disorders, such as chylomicron retention disease (CMRD; MIM 246700) and Anderson disease (MIM 607689). In contrast, *SAR1A* mutations were not identified in either of these syndromes ([@b9]). To date, there are no known human *SAR1A* human mutations although this association study suggests that some SNPs could subtly alter *SAR1A* expression or function.

Finally, others have also examined *SAR1A* polymorphisms and haemolysis-driven phenotypes of SCD, such as leg ulcers, but these studies have not demonstrated significant associations ([@b12]). Similarly in this study, there was no association between *SAR1A* SNPs and pulmonary hypertension (e.g. tricuspid regurgitant jet velocity \>2·5 m/s, data not shown), which is also believed to be a haemolysis-associated complication of SCD. However, it is worthwhile to note that the Nolan leg ulcer study evaluated SNPs (rs870801 in intron 1 and rs2271690 in intron 3) that are located approximately 10 kb pairs apart from one another within a 20·3 kb gene (*SAR1A*). While these negative results suggest an unlikely role for involvement of *SAR1A* in response to haemolysis in SCD, neither study utilized high density, haplotype tagged markers to interrogate this gene. Additional study of the role of this gene in response to HC therapy and haemolysis are warranted before firm conclusions can be made.

In conclusion, *SAR1A* polymorphisms might contribute to the regulation of HbF expression and modulate patient responses to HC in sickle cell anaemia. However, replication in independent populations and targeted functional studies are needed to confirm the validity of these associations.
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